In June 2022, the Government of Canada established a long-term agreement with Moderna for the domestic production of messenger RNA (mRNA) vaccines in Canada.
Kane Biotech Inc.
Kane Biotech is a Winnipeg based biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms.
Biofilms develop when bacteria and other microorganisms form a protective matrix that act as a shield against attacks. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human and animal health problems, such as tooth decay or medical device and wound-associated infections.
Kane Biotech uses patent-protected technologies that are based on molecular mechanisms of biofilm formation/dispersal for finding compounds that inhibit or disrupt biofilms. The company has evidence these technologies have potential to significantly improve the ability to prevent, and/or destroy, biofilms in several medical, commercial and industrial applications.
Kane Biotech has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.